A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Trial details
- Registry ID
- NCT07012395
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as SPY003-207
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative ColitisNCT07012395 | SYRE | Phase 2 | Recruiting | 2027-06Estimated |
| Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBDNCT07652294 | SYRE | Phase 2 | Enrolling by invitation | 2029-03-02Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |